(Information sent by the signatory company)
– Peijia Medical Limited and inQB8 Medical Technologies, LLC report the first successful human implantation of the MonarQ transcatheter tricuspid valve replacement system
SUZHOU, China, Nov. 25, 2022 /PRNewswire/ — inQB8 Medical Technologies, LLC (inQB8), in association with Peijia Medical Limited (Peijia, (9996.HK)), today announced that it has successfully implanted the transcatheter tricuspid valve. MonarQ in a 75-year-old woman suffering from severe torrential tricuspid valve regurgitation. The TTVR Trans-Jugular procedure was performed on November 21, 2022, for compassionate reasons at the Heart Centre, Rigshospitalet University Hospital, Copenhagen, Denmark, by interventional cardiologists Professor Lars Søndergaard, M.D., Professor Ole De Becker M.D., and cardiothoracic surgeon Morten Smerup, M.D., Jacob Moller M.D. (echocardiographer), Hasse Moeller-Sorensen. M.D. (anesthesiologist), along with inQB8 Co-Founder, CEO, CMO and Cardiac Surgeon Arshad Quadri, M.D.
“We are grateful to have had the opportunity to work again with Dr. Quadri, together with the inQB8 team, to provide an exciting new treatment option for this patient for whom no other alternatives were available,” said Dr. Lars Søndergaard. . “Due to multiple risk factors and anatomic constraints, neither traditional tricuspid valve surgery nor edge-to-edge transcatheter tricuspid valve repair were options for this patient. Through careful review and consideration within our team, we determined that TTVR with the MonarQ system could offer the potential to alleviate symptoms and provide a better quality of life for this patient. The valve was successfully implanted with excellent function.”
“I am delighted to be working with Dr. Lars Søndergaard and his experienced team at Rigshospitalet on this next chapter of transcatheter valve development. The MonarQ Transcatheter Tricuspid Valve (TTV) has a unique BioDynamic connection system that uses and preserves the natural motion of the heart. to secure implantation to native leaflets, distribute systolic loads, and minimize paravalvular leaks in a wide range of native annulus sizes,” explained Arshad Quadri, M.D., cardiac surgeon and co-founder, CEO, and CMO of inQB8. “By addressing not only the anatomical requirements but also the physiologic needs of the tricuspid valve, Dr. Quadri and I believe the MonarQ TTVR System will turn the page in the treatment of tricuspid valve regurgitation, an extremely insidious and disabling disease of this tricuspid valve.” forgotten valve,” said Brent Ratz, co-founder and CEO of inQB8.
“In recent years, the need for a transcatheter tricuspid valve replacement solution has become increasingly clear. As Peijia looks to expand its presence globally and develop its structural heart portfolio, our combined investment in inQB8 and MonarQ TTVR technology was a natural choice,” said Dr. Michael Zhang, President and CEO of Peijia Medical. “The successful first-in-human implantation of MonarQ marks an exciting first step in bringing this life-saving and life-enhancing technology to more and more patients around the world,” said Dr. JianFong Tan, CTO of Peijia Medical.
Acerca de Peijia Medical Limited
Peijia Medical (09996.HK) was established in the year 2012 and is headquartered in Suzhou, China. Peijia Medical focuses on the high-growth interventional medical device market in China and aims to become a world-renowned medical device platform that provides comprehensive treatment solutions for structural heart and neurovascular diseases.
About inQB8 Medical Technologies, LLC
inQB8 Medical Technologies, LLC is a privately held medical device incubator headquartered in Massachusetts with additional offices in Irvine, California. It is the second collaboration between Arshad Quadri, MD, and J. Brent Ratz, MBA, whose partnership began 16 years ago with the co-founding of CardiAQ Valve Technologies, the world’s first transcatheter transseptal mitral valve replacement (TMVR) system. inQB8 focuses on developing novel international solutions for major cardiovascular diseases, including structural heart problems, aortic disease, and heart failure, accelerating projects through prototyping, bench testing, and preclinical until they are ready for acquisition or advanced as a separate independent cardiovascular start -UPS. In June 2021, Peijia Medical announced a strategic partnership with inQB8 and agreed to acquire MonarQ TTVR technology, which inQB8 continues to develop on its behalf.
All forward-looking statements are subject to risks and uncertainties as described in Peijia Medical’s periodic reports filed with HKEx. Actual results may differ materially from anticipated results.
Caution: The MonarQ Transcatheter Tricuspid Valve Replacement System is in the early stages of development. It will not be available for clinical trials until further notice and is NOT available for sale.
Logo – https://mma.prnewswire.com/media/1954815…
Logo – https://mma.prnewswire.com/media/1954814…
View original content: https://www.prnewswire.com/news-releases/peijia-medical-limited-e-inqb8-medical-technologies-llc-informan-del-primer-implante-del-sistema-monarq-301687247.html
